ELOVL5: Inching closer to a new therapeutic strategy for prostate cancer

Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zininos I, Dehairs J, Burvenich IJG, Zadra G, Chetta P, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokioou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Res. 2021 Feb 5:canres.2511.2020. doi: 10.1158/0008-5472.CAN-20-2511. Epub ahead of print. PMID: 33547161.